SHPG News and Press, Shire plc From 09/12/19

As the US Department of Health and Human Services notes, Alzheimer’s disease (AD) is a degenerative brain disorder that results in cognitive decline and basic thinking skills which slowly gets worse over time. According to a 2019 Alzheimer’s disease facts and figures re...

With several licenses acquired from well-known pharmaceutical companies, Mirum Pharmaceuticals ( MIRM ) is a name to be followed carefully after the IPO. The most appealing is its pipeline. The company owns two product candidates at Phase 3 of development and several candidates at Phase 2 of d...

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins’ 13F portfolio on a quarterly basis. It is based on Robbins’ regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Larry Robbins’ Glenview Capital Mana...

This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Dan Loeb’s Third Point Portfoli...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking John Paulson's Pau13lson & Company Portfolio ser...

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins’ 13F portfolio on a quarterly basis. It is based on Robbins’ regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Larry Robbins’ Glenview Capital Mana...

This article is part of a series that provides an ongoing analysis of the changes made to David Abrams’ 13F portfolio on a quarterly basis. It is based on Abrams’ regulatory 13F Form filed on 02/14/2019. Please visit our Tracking David Abrams’ Abrams Capital Management ...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...

Introduction I always look for new opportunities and I return to my fallen angels who cut their dividend to see whether they offer an attractive opportunity. I have decent exposure to healthcare but will always consider adding quality stocks to my portfolio. One of the companies in the hea...

Viking Therapeutics (NASDAQ: VKTX ) +8.4% and Madrigal Pharmaceuticals (NASDAQ: MDGL )  +3.3% after-hours as Gilead’s (NASDAQ: GILD ) study designed to evaluate a chronic liver disease drug failed to meet its primary endpoint ; GILD -3.6% . More news on: Viking Therapeutic...